Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment

Cochrane Database of Systematic Reviews

Volumn 2023, Issue 1, 2012, Pages

  Robertson, Lindsay ^a   Ghouri, Maaz A ^b   Kovacs, Flora ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

HUMAN; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STENOSIS, OCCLUSION AND OBSTRUCTION;

ANGIOPLASTY, BALLOON; ANTICOAGULANTS; CONSTRICTION, PATHOLOGIC; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84867907090     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002071.pub3     Document Type: Review

References (79)

1. Ansel GM, Silver MJ, Botti CF Jr, Rocha-Singh K, Bates MC, Rosenfield K, et al. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial. Catheterization and Cardiovascular Interventions 2006;67(2):288-97. x-wiley/crsRef/22482669
2. Baumgartner I. Reopro and peripheral arterial intervention to improve clinical outcome in patients with peripheral arterial disease (RIO Trial). Clinical Research in Cardiology 2007;96(11):783-4. x-wiley/crsRef/22482671
3. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology 1994;193(2):567-71. x-wiley/crsRef/22482673
4. Dörffler-Melly J, Mahler F, Do DD, Triller J, Baumgartner I. Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience. Radiology 2005;237(3):1103-9. x-wiley/crsRef/22482675
5. Duda SH, Tepe G, Luz O, Ouriel K, Dietz K, Hahn U, et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis. Radiology 2001;221(3):689-96. x-wiley/crsRef/22482677
6. Heinz M, Theiss W, van de Flierdt E, Söhngen M. The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty [Der Einfluss von Taprosten auf Thrombozytenaktivierung und klinischen Verlauf nach perkutaner transluminaler Angioplastie]. Vasa 1996;25(1):65-72. x-wiley/crsRef/22482679
7. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990;41(4):263-9. x-wiley/crsRef/22482681
8. Hess H, Müller-Fassbender H, Ingrisch H, Mietaschk A. Prevention of re-occlusion after recanalisation of occluded arteries by the catheter method (author's transl) [Verhütung von Wiederverschlüssen nach Rekanalisation obliterierter Arterien mit der Kathetermethode]. Deutsche Medizinische Wochenschrift 1978;103(50):1994-7. x-wiley/crsRef/22482683
9. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery 2008;48(1):144-9. x-wiley/crsRef/22482685
10. Koppensteiner R, Spring S, Amann-Vesti BR, Meier T, Pfammatter T, Rousson V, et al. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. Journal of Vascular Surgery 2006;44(6):1247-53. x-wiley/crsRef/22482687
11. Mahler F, Schneider E, Gallino A, Bollinger A. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoropopliteal PTA. Vasa 1987;16(4):381-5. x-wiley/crsRef/22482689
12. Minar E, Ahmadi A, Koppensteiner R, Maca T, Stümpflen A, Ugurluoglu A, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995;91(8):2167-73. x-wiley/crsRef/22482691
13. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, et al. Adjunctive parental therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. Journal of Vascular Surgery 2007;45(5):953-61. x-wiley/crsRef/22482693
14. Pilger E, Lammer J, Bertuch H, Stark G, Decrinis M, Pfeiffer KP, et al. Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation 1991;83(1):141-7. x-wiley/crsRef/22482695
15. Creutzig A, Ranke C, Luska G, Wagner HH, Galanski M, Bode Boger S, et al. Controlled trial of high versus low dose aspirin treatment after PTA in patients with peripheral vascular disease. Annals of Hematology 1994;68(Suppl 1):A74. x-wiley/crsRef/22482697
16. Ranke C, Creutzig A, Luska G, Wagner HH, Galanksi M, Bode-Böger S, et al. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clinical Investigator 1994;72(9):673-80. x-wiley/crsRef/22482698
17. Ranke C, Creutzig A, Luska G, Wagner HH, Galanskî M, Bode-Böger S, et al. Dose-dependent side effects of acetylsalicylic acid therapy. Results of a prospective randomized clinical study in patients with peripheral arterial occlusive disease [Dosisabhängige Nebenwirkungen der Acetylsalicylsäuretherapie]. Medizinische Klinische 1993;88(10):571-6. x-wiley/crsRef/22482699
18. Ranke C, Hecker H, Creutzig A, Alexander K. Aspirin dose and progression of peripheral vascular disease: results of a controlled clinical trial. Annals of Hematology 1994;68(Suppl 1):A74. x-wiley/crsRef/22482700
19. 1- receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. Angiology 2008;58(6):710-6. x-wiley/crsRef/22482702
20. Schneider E, Mahler F, Do DD, Biland l, Widmer LK, Bollinger A. Zur Rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA): Antikoagulation versus Ticlopidin. Vasa 1987;16(Suppl 20):355-6. x-wiley/crsRef/22482704
21. Schweizer J, Müller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 2001;52(10):659-69. x-wiley/crsRef/22482706
22. Study group on pharmacological treatment after PTA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. European Journal of Vascular Surgery 1994;8(1):83-8. x-wiley/crsRef/22482708
23. Tan JY, Shi WH, He J, Zhu L, Wang TP, Yu B. A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting [Chinese]. National Medical Journal of China 2008;88(12):812-5. x-wiley/crsRef/22482710
24. Wang J, Zhu YQ, Li MH, Zhao JG, Tan HQ, Wang JB, et al. Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. Journal of Vascular and Interventional Radiology 2011;22(7):987-94. x-wiley/crsRef/22482712
25. Wang J, Zhu YQ, Liu F, Li MH, Zhao JG, Tan HQ, et al. Batroxobin for prevention of restenosis in diabetic patients after infrapopliteal arterial angioplasty: a small randomized pilot trial. Annals of Vascular Surgery 2010;24(7):876-84. x-wiley/crsRef/22482713
26. Weichert W, Meents H, Abt K, Lieb H, Hach W, Krzywanek HJ, et al. Acetylsalicylic acid--reocclusion--prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. Vasa 1994;23(1):57-65. x-wiley/crsRef/22482715
27. Allie DE, Lirtzman MD, Wyatt CH, Keller VA, Khan MH, Khan MA, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal iliac interventions. Journal of Invasive Cardiology 2003;15(6):334-42. x-wiley/crsRef/22482717
28. Bulvas M, Chochola M, Herdova J, Sommerova Z, Urbanova R. The effect of heparin sulphate on percutaneous transluminal angioplasty in the vessels supplying the lower extremities [Vliv heparansulfatu na efekt perkutanni transluminalni angioplastiky v oblasti tepen zasobujicich dolni koncetiny]. Casopis Lekaru Ceskych 1996;135(14):445-9. x-wiley/crsRef/22482719
29. Horrocks M, Horrocks EH, Murphy P, Lane IF, Ruttley MS, Fligelstone LJ, et al. The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. International Angiology 1997;16(2):101-6. x-wiley/crsRef/22482721
30. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clinical Journal of the American Society of Nephrology 2008;3(4):1034-40. x-wiley/crsRef/22482723
31. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thrombosis and Haemostasis 1997;78(3):1003-7. x-wiley/crsRef/22482725
32. Shammas NW, Lemke JH, Dippel EJ, McKinney DE, Takes VS, Youngblut M, et al. Bivalirudin in peripheral vascular interventions: a single center experience. Journal of Invasive Cardiology 2003;15(7):401-4. x-wiley/crsRef/22482727
33. Stavropoulos SW, Solomon JA, Soulen MC, Clark TW, Shlansky-Goldberg RD. Use of abciximab during infrainguinal peripheral vascular interventions: initial experience. Radiology 2003;227(3):657-61. x-wiley/crsRef/22482729
34. Strecker EP, Boos IB, Gottmann D, Vetter S. Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results. European Radiology 2004;14(2):302-8. x-wiley/crsRef/22482731
35. Tetteroo E, Mali WP, Rienks R, van Kester JA, Banga JD. The significance of coumarin anticoagulation in laser assisted percutaneous transluminal angioplasty of femoropopliteal arterial obstructions. European Journal of Radiology 1995;19(2):86-90. x-wiley/crsRef/22482733
36. Zeitler E, Reichold J, Schoop W, Loew D. Effect of acetylsalicylic acid on early results following percutaneous recanalisation of arterial occlusions (Dotter's method) [Einfluss von Acetylsalicylsäure auf das Frühergebnis nach perkutaner Rekanalisation arterieller Obliterationen nach Dotter]. Deutsche Medizinische Wochenschrift 1973;98(26):1285-8. x-wiley/crsRef/22482735
37. Mirror trial - follow-up management of peripheral arterial intervention with clopidogrel. http://clinicaltrials.gov/ct2/show/NCT00163267 (accessed 2 May 2012). x-wiley/crsRef/22482737
38. Block PC, Myler RK, Stertzer S, Fallon JT. Morphology after transluminal angioplasty in human beings. New England Journal of Medicine 1981;305(7):382-5.
39. Sanofi-Aventis. Press releases. http://en.sanofi-aventis.com/press/ppc_17142.asp (accessed 27 September 2004).
40. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682-7.
41. Decrinis M, Pilger E, Stark G, Lafer M, Obernosterer A, Lammer J. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. European Heart Journal 1993;14(3):297-305.
42. Do DD, Triller J, Walpoth BH, Stirnemann P, Mahler F. A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions. Cardiovascular and Interventional Radiology 1992;15(5):306-12.
43. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. Circulation 1964;30:654-70.
44. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106(12):1505-9.
45. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. American Heart Journal 1989;117(4):777-82.
46. Ferns GAA, Stewart-Lee AL, Anggard EE. Arterial response to mechanical injury: balloon catheter de-endothelialization. Atherosclerosis 1992;92(2-3):89-104.
47. Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstorungen]. Helvetica Chirurgica Acta 1954;5/6:499-533.
48. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thrombosis and Haemostasis 1995;74(1):552-9.
49. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation 1984;70(4):619-23.
50. Grüntzig A, Hopff H. Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique). Deutsche Medizinische Wochenschrift 1974;99(49):2502-10, 2511.
51. Haudenschild CC. Pathophysiology of reocclusion and restenosis. Fibrinolysis 1995;9(Suppl 1):44-7.
52. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral arterial occlusive disease. A prospective double-blind arteriographically controlled trial. Lancet 1985;1(8426):415-9.
53. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17(1):1-12.
55. Jorgensen B, Meisner S, Holstein P, Tonnesen KH. Early rethrombosis in femoropopliteal occlusions treated with percutaneous transluminal angioplasty. European Journal of Vascular Surgery 1990;4(2):149-52.
56. Mahler F, Baumgartner I, Do DD. Stenting of the peripheral, renal and supraaortic arteries and the aorta. Schweizerische Medizinische Wochenschrift 1999;129(10):399-409.
57. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Techniques in Vascular and Interventional Radiology 2004;7(1):2-5.
58. Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlbock M, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000;102(22):2694-9.
59. Moneta GL, Strandness DE Jr. Peripheral arterial duplex scanning. Journal of Clinical Ultrasound 1987;15(9):645-51.
60. Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology 1985;156(1):73-7.
61. Parent FN 3rd, Bernhard VM, Pabst TS 3rd, McIntyre KE, Hunter GC, Malone JM. Fibrinolytic treatment of residual thrombus after catheter embolectomy for severe lower limb ischemia. Journal of Vascular Surgery 1989;9(1):153-60.
62. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound in Medicine and Biology 1992;18(5):433-40.
63. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
64. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. Journal of Vascular Surgery 2001;33(4):805.
65. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 2004;232(2):516-21.
66. Schillinger M, Mlekusch W, Haumer M, Sabeti S, Ahmadi R, Minar E. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions: 1-year follow-up. Journal of Endovascular Therapy 2003;10(2):288-97.
67. Schneider E. Percutaneous transluminal angioplasty, local thrombolysis and percutaneous thrombus extraction in the treatment of arterial occlusions of the extremities [Die perkutane transluminale Angioplastie, lokale Thrombolyse und perkutane Thrombenextraktion in der Behandlung von Extremitäten Arterienverschlüssen]. Der Internist 1989;30(7):440-6.
68. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. American Journal of Cardiology 1998;81(7 Suppl 1):14E-17E.
69. Shammas NW, Lemke JH, Dippel EJ, McKinney DE, Takes VS, Youngblut M, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. Journal of Invasive Cardiology 2003;15(5):242-6.
70. Strecker EP, Berg G, Schneider B, Freudenberg N, Weber H, Wolf RD. A new vascular balloon-expandable prosthesis. Experimental studies and first clinical results. Journal of Interventional Radiology 1988;3(2):59-62.
71. Trans Atlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease. Treatment of intermittent claudication. Journal of Vascular Surgery 2000;31(1 Pt 2):S97-113.
72. Tsakiris DA, Tschöpl M, Jäger K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999;142(1):193-200.
73. Tschöpl M, Tsakiris DA, Marbet GA, Labs KH, Jaeger K. Role of haemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arteriosclerosis, Thrombosis and Vascular Biology 1997;17(11):3208-14.
74. Vogel TR, Shindelman LE, Nackman GB, Graham AM. Efficacious use of nitinol stents in the femoral and popliteal arteries. Journal of Vascular Surgery 2003;38(6):1178-84.
75. Ward MR, Tsao PS, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arteriosclerosis, Thrombosis and Vascular Biology 2001;21(2):208-13.
76. Watson HR, Bergqvist D. Antithrombotic agents after peripheral transluminal angioplasty: a review of the studies, methods and evidence for their use. European Journal of Vascular and Endovascular Surgery 2000;19(5):445-50.
77. Wentzel JJ, Gijsen FJ, Stergiopulos N, Serruys PW, Slager CJ, Krams R. Shear stress, vascular remodeling and neointimal formation. Journal of Biomechanics 2003;36(5):681-8.
78. Zehnder T, Birrer M, Do DD, Baumgartner I, Triller J, Nachbur B, et al. Percutaneous catheter thrombus aspiration for acute or subacute arterial occlusion of the legs: how much thrombolysis is needed? European Journal of Vascular and Endovascular Surgery 2000;20(1):41-6.
79. Dörffler-Melly J, Koopmann MMW, Adam DJ, Prins MH, Büller HR. Prevention of early occlusion in symptomatic PAOD patients undergoing peripheral catheter intervention. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No: CD002071. [DOI: 10.1002/14651858.CD002071.pub2]